Ares Capital Stock Q4: A 10%-Yielding Piggy Bank

Sezeryadigar Ares Capital (NASDAQ:ARCC)’s shares gained more than 1% after the BDC reported better than expected results for the December quarter. Ares Capital’s portfolio is performing well, net investment income is growing by the double-digits, and the BDC has seen an expansion in its debt yields due to higher interest rates in the U.S. economy….

Read More

BYD Electronic Stock: Preliminary Results And Major Acquisition Draw Attention

AlexandrBognat/iStock via Getty Images Elevator Pitch I have a Buy investment rating for BYD Electronic (International) Company Limited (OTCPK:BYDIF) (OTCPK:BYDIY) [285:HK]. Previously, I touched on the risk relating to the company’s customer concentration, and BYDIF’s efforts to diversify its client mix in my June 1, 2020 article. In its 1H 2023 interim report, BYD Electronic…

Read More

monday.com Stock: Ripe For A Breather (Rating Downgrade) (NASDAQ:MNDY)

SOPA Images/LightRocket via Getty Images Brief Review Of monday.com’s Q4 2023 Report Earlier this morning, monday.com Ltd. (NASDAQ:MNDY) reported stronger-than-expected numbers for Q4 2023, with quarterly revenues growing by 35% y/y to $202.6M and the Work OS platform company reporting a narrower-than-expected GAAP operating loss of -$1.1M [GAAP operating margin of -1% vs. -7% from…

Read More

Bitcoin Hits $50,000 For The First Time Since 2021

Bitcoin has surged past the $50,000 mark today, according to CoinMarketCap data, reaching this milestone for the first time since December 2021.  CoinMarketCap The breakthrough marks a significant recovery for Bitcoin, which faced massive volatility and fluctuations over the last couple years, reaching lows of around $16,000. Bitcoin’s resilience and upward trajectory underscore its status as a…

Read More

Staying Selective In Emerging Markets

2d illustrations and photos Transcript We like emerging markets as upbeat risk appetite carries on. We see broader support for emerging market assets as markets price in a rosy macro outlook and fears of recession have faded. But selectivity is key. 1) Broader support for EM As markets have priced in rate cuts, 10-year Treasury…

Read More

monday.com Ltd. (MNDY) Q4 2023 Earnings Call Transcript

monday.com Ltd. (NASDAQ:MNDY) Q4 2023 Earnings Conference Call February 12, 2024 8:30 AM ET Company Participants Byron Stephen – Director of IR Roy Mann – Co-CEO Eran Zinman – Co-CEO Eliran Glazer – CFO Conference Call Participants Kash Rangan – Goldman Sachs Pinjalim Bora – JPMorgan Brent Bracelin – Piper Sandler Steve Enders – Citi…

Read More

Navigating The Now: Events Leading Up To The Bitcoin ETFs

Over the past months, Bitcoin ETFs dominated the cryptocurrency, finance, and investing discourse. A flurry of attention-focused articles on the latest wave of spot Bitcoin ETF applications captured the collective interest. Stakeholders speculated on their implications. Following heightened anticipation at the beginning of 2024, the Securities and Exchange Commission of the United States (US SEC)…

Read More

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson’s Prospects

koto_feja Intro Annovis Bio (NYSE:ANVS) is set to report the results of its Phase 3 trial in early-stage Parkinson’s disease (PD) in the coming weeks. The company’s lead asset, buntanetap (formerly known as posiphen), is a translational inhibitor of alpha synucelein (associated with PD), amyloid precursor protein (Alzheimer’s), TDP-43 (ALS), and other proteins associated with…

Read More

RQI: A Stellar Closed End Fund Currently Overvalued

Wong Yu Liang/Moment via Getty Images For the decade following the financial crisis, REITs capitalized on a perpetually low interest rate environment to fire up the commercial real estate engine. Declining yields and capitalization rates supported rising REIT valuations and property values. REITs shined during this period. The situation changed dramatically following the pandemic era….

Read More

Alphatec Holdings: Taking Market Share Amid Strong Execution – Buy (NASDAQ:ATEC)

Natali_Mis Note: I have discussed Alphatec Holdings, Inc. (NASDAQ:ATEC) previously, so investors should view this article as an update to my earlier coverage of the company. Introduction / Discussion Of Past Performance Alphatec Holdings, Inc. or “ATEC” is a medical technology company that designs, develops, and advances technologies for the surgical treatment of spinal disorders….

Read More

Anglo American: Too Cheap To Ignore (OTCMKTS:AAUKF)

Bloomberg/Bloomberg via Getty Images Following Anglo American (OTCQX:NGLOY) (OTCQX:AAUKF) reset expectations in early December 2023, the company’s Q4 2023 realized commodity prices and operating performances align with previously communicated guidance. We can conclude that “No news is good news.” That said, Anglo is one of the largest diversified mining companies worldwide. It is headquartered in…

Read More

CEL-SCI: Fabulous Story Stock Works To Pass Muster With FDA (NYSE:CVM)

Kharchenko_irina7/iStock via Getty Images I am a long-term follower and chronicler of CEL-SCI (NYSE:CVM). My initial CEL-SCI article was 08/2019’s CEL-SCI: A Risky Bet. My most recent was 07/2023’s “Cel-Sci: Would-Be Cancer Giant Taking Baby Steps”. In this article I evaluate its investment prospects based up on its latest investor communications. These include: 10/25/2023 –…

Read More

Unibail-Rodamco-Westfield Is An Income Investment Again (UNBLF)

Manuel Milan Unibail-Rodamco-Westfield (OTCPK:UNBLF) has announced the distribution of a dividend related to 2023 earnings, making it attractive again for income investors, plus its valuation is quite low making it an interesting play within the European REIT sector. As I’ve analyzed in a previous article, Unibail’s restructuring phase was almost completely done and the company…

Read More

Altimmune’s Pemvidutide Lacks Differentiation In Obesity Treatment (NASDAQ:ALT)

bymuratdeniz/E+ via Getty Images Pemvidutide’s Pounds and Problems: Altimmune’s Balancing Act Since December, Altimmune’s (NASDAQ:ALT) stock has nearly tripled since revealing obesity data (MOMENTUM) in late November for their GLP-1/glucagon agonist, pemvidutide (subcutaneous weekly). Altimmune is not the first to study GLP-1/glucagon agonism. Several drugs are currently in development, including Merck’s (MRK) efinopegdutide, Eli Lilly’s…

Read More

TrueCar May Be On The Cusp Of Growth, Profitability, And Higher Share Prices (NASDAQ:TRUE)

Marat Musabirov Thesis With fourth-quarter 2023 earnings results expected shortly, investors and potential investors will wonder if TrueCar, Inc. (NASDAQ:TRUE) can maintain the momentum it gained in the third quarter. In its third-quarter earnings release, the company suggested it had turned a corner, with revenue and earnings again on the rise. The odds seem in…

Read More